Journal
EXPERIMENTAL NEUROLOGY
Volume 215, Issue 2, Pages 397-400Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.expneurol.2008.10.001
Keywords
-
Categories
Funding
- VISN 17, Department of Veterans Affairs
- Department of Veterans Affairs
- Viragh Foundation
- Fritz-Thyssen Foundation
- University of Dusseldorf
Ask authors/readers for more resources
Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and proinflammatory cytokines IFN gamma and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available